- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02781233
A Progressive Resistance Training Program in Patients With Haemophilia
The Impact of Progressive Resistance Training on Quality of Life in Patients With Haemophilia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46010
- University of Valencia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of haemophilia A or B
- willingness to exercise twice a week during the training program and to complete the pre- and post-program evaluations
- approval by their hematologist to participate in the exercise program
- age between 18 and 60 years
- informed consent signed.
Exclusion Criteria:
- the inability to attend exercise sessions at least twice a week for 6 consecutive weeks
- non adherence to instruction on proper exercise technique
- surgical procedures performed 6 weeks prior to or during the exercise program
- participation in any other form of exercise, including rehabilitation, during the study; (5) changes in medication during the study
- a major bleeding episode that posed a risk or prevented exercise
- History of FVIII inhibitor (titer ≥ 0.6 BU [Bethesda unit]) or detectable FVIII inhibitors at screening (titer ≥ 0.4 BU)
- Another haemostatic defect
- Need for major surgery
- Withdrawal of informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Training group
Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
|
Progressive resistance training program
|
|
Placebo Comparator: Control group
Usual daily activities
|
Usual daily activities
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Muscle strength
Time Frame: baseline and 8 weeks
|
For measuring the isometric knee flexion and extension, ankle plantarflexion and dorsiflexion strength and isometric elbow flexion and extension strength, a portable hand-held dynamometer will be used (Nicholas Manual Muscle Tester, Lafayette Instruments, Indiana, USA).
|
baseline and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Timed Up and Go
Time Frame: baseline and 8 weeks
|
The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. |
baseline and 8 weeks
|
|
Change in Haemophilia Quality of life questionnaire (A36 Haemophilia-QoL® )
Time Frame: baseline and 8 weeks
|
The Haemophilia-QoL questionnaire is a self-report modular instrument that assesses nine relevant HRQoL domains for patients with haemophilia (e.g.
physical health, daily activities, joint damage, pain, treatment satisfaction, treatment difficulties, emotional functioning, mental health, relationships and social activity).
|
baseline and 8 weeks
|
|
Change in Bleedings
Time Frame: daily (during the 8 weeks of intervention)
|
Number of Bleedings During the study
|
daily (during the 8 weeks of intervention)
|
|
Change in viscoelastic properties (rectus femoris)
Time Frame: baseline and 8 weeks
|
Myoton Pro
|
baseline and 8 weeks
|
|
Change in sit-to-stand test
Time Frame: baseline and 8 weeks
|
The time taken for the participant to stand up and sit down from a standard 45 cm chair with arms three times, as quickly as possible, was measured.
|
baseline and 8 weeks
|
|
Change in Haemophilia Activities List questionnaire
Time Frame: baseline and 8 weeks
|
The Haemophilia Activities List questionnaire measures the impact of hemophilia on self-perceived functional abilities in adults. It contains 42 multiple choice questions in seven domains: Lying/sitting/kneeling/standing (8 items) Functions of the legs (9 items) Functions of the arms (4 items) Use of transportation (3 items) Self-care (5 items) Household tasks (6 items) Leisure activities and sports (7 items) The most important outcomes are the overall sum score and three component scores relating to upper extremity activities, basic lower extremity activities, and complex lower extremity activities. A domain score for each of the seven domains can also be calculated. |
baseline and 8 weeks
|
|
Change in The Haemophilia Joint Health Score (HJHS)
Time Frame: baseline and 8 weeks
|
The HJHS measures joint health, in the domain of body structure and function (i.e.
impairment), of the joints most commonly affected by bleeding in hemophilia: the knees, ankles, and elbows.The HJHS 2.1 provides a total score (higher score is worse; max=124), joint specific scores, and a global gait score.
|
baseline and 8 weeks
|
|
Change in Pain
Time Frame: baseline and 8 weeks
|
11-point numerical pain rating scale with higher score meaning higher pain
|
baseline and 8 weeks
|
|
Change in workability index
Time Frame: baseline and 8 weeks
|
workability index with single question
|
baseline and 8 weeks
|
|
Change in analgesics use (days/week)
Time Frame: baseline and 8 weeks
|
The number of days the participants used analgesics during the last week
|
baseline and 8 weeks
|
|
Change in Range Of Motion (ROM)
Time Frame: baseline and 8 weeks
|
elbow extensio/flexion, ankle dorsiflexion/plantar flexion and knee flexion/extension ROM with a goniometer
|
baseline and 8 weeks
|
|
Change in Kinesiophobia
Time Frame: baseline and 8 weeks
|
Tampa Scale of Kinesiophobia (TSK-11SV) used to assess changes in fear of movement
|
baseline and 8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Felipe Querol-Fuentes, MD, PhD, University of Valencia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H15-29504
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Haemophilia
-
Al-Azhar UniversityActive, not recruiting
-
University of ValenciaUnknown
-
Novo Nordisk A/SCompletedHaemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BFrance, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
-
Novo Nordisk A/SCompletedEpidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BIndia, Morocco, South Africa, Oman
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BSpain
-
Investigación en Hemofilia y FisioterapiaCompleted
-
Novo Nordisk A/SWithdrawnHealthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsSpain, Canada, United Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsBrazil
Clinical Trials on Normal daily activities
-
University of ValenciaUnknown
-
Vrije Universiteit BrusselUnknownLower Limb Amputation Above Knee (Injury)Belgium
-
Radboud University Medical CenterUniversitas TarumanagaraCompletedDepressive Symptoms | Well-beingIndonesia
-
McMaster UniversityCanadian Diabetes AssociationCompleted
-
Universitat Jaume ICompletedChronic Pain | FibromyalgiaSpain
-
Vilnius UniversityCompletedCardiac SurgeryLithuania
-
Izmir Katip Celebi UniversityCompletedIdiopathic Pulmonary Fibrosis | Activity, MotorTurkey
-
Universitat Jaume IUnknown
-
WeiJin ZhangCompleted
-
University of ValenciaUniversity of TwenteCompletedNot Flourishing PopulationSpain, Netherlands